Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q-linea ABCHIX:QLINES 64 Days Sales Outstanding is 185.91 as of Jun. 2026, which is 52% above its 10-year median of 122.40. GuruFocus rates CHIX:QLINES with a GF Score™ of 64/100 and a GF Value™ of kr1,615.96. The stock has 3 warning signs investors should review. Among 809 Medical Devices & Instruments companies, Q-linea AB ranks worse than 88.38% on this metric.
Q-linea AB's average Accounts Receivable for the
three
months ended in Jun. 2026 was kr3.06 Mil. Q-linea AB's Revenue for the
three
months ended in Jun. 2026 was kr1.50 Mil.
Hence, Q-linea AB's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 185.91.
The historical rank and industry rank for Q-linea AB's Days Sales Outstanding or its related term are showing as below:
CHIX:QLINEs'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.06 Med: 122.4 Max: 3690.56
Current: 137.13
During the past 11 years, Q-linea AB's highest Days Sales Outstanding was 3690.56. The lowest was 45.06. And the median was 122.40.
CHIX:QLINEs's Days Sales Outstanding is ranked worse than 88.38% of 809
companies
in the Medical Devices & Instruments industry
Industry Median: 64.94
vs CHIX:QLINEs: 137.13
Q-linea AB's Days Sales Outstanding
declined
from Jun. 2025 (186.33) to Jun. 2026 (185.91).
Q-linea AB (CHIX:QLINEs) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Q-linea AB Days Sales Outstanding Related Terms
Q-linea AB Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Q-linea AB's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:QLINES vs ABT, SYK, MDT: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Q-linea AB's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Q-linea AB's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 185.91 mean?
Q-linea AB (CHIX:QLINES) has a Days Sales Outstanding of 185.91 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Q-linea AB and its competitors. This is 52% above median its historical median of 122.40. Over the past decade, Q-linea AB's Days Sales Outstanding has ranged from 45.06 to 3,690.56. According to the industry distribution chart, Q-linea AB ranks #715 out of 809 companies in the Medical Devices & Instruments industry, placing it in the top 88.4%.
Is Q-linea AB's Days Sales Outstanding too high?
Q-linea AB's current Days Sales Outstanding of 185.91 is 52% above median its 10-year median of 122.40. Over the past 10 years, this metric has ranged from a low of 45.06 to a high of 3,690.56. The Medical Devices & Instruments industry median Days Sales Outstanding is 64.94. Q-linea AB's value of 185.91 is 186.3% above this industry median. Based on the distribution chart, Q-linea AB ranks #715 out of 809 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Q-linea AB has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Days Sales Outstanding compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #715 out of 809 companies for Days Sales Outstanding. This places Q-linea AB in the lower half of its industry. The industry median Days Sales Outstanding is 64.94. Q-linea AB's value of 185.91 is 186.3% above this benchmark. Historically, Q-linea AB's own Days Sales Outstanding has ranged from 45.06 to 3,690.56 over the past decade. While the company's 10-year median is 122.40 vs. the industry median of 64.94, Q-linea AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 64.94, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-linea AB's current Days Sales Outstanding of 185.91 is 186.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Q-linea AB and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 64.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-linea AB's current Days Sales Outstanding is 185.91, which is 52% above median its own 10-year median of 122.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current Days Sales Outstanding of 185.91. The stock's GF Value™ is kr1,615.96, compared to a current price of kr1,610.00 — trading 0.4% below its estimated fair value. The current Days Sales Outstanding is 185.91, which is 52% above median its 10-year median of 122.40 and 186.3% above the Medical Devices & Instruments industry median of 64.94. Q-linea AB's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current Days Sales Outstanding is 185.91 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 0.4% below its estimated GF Value™ of kr1,615.96.
Key valuation signals for CHIX:QLINES:
Days Sales Outstanding: 185.91 (52% above median its 10-year median of 122.40)
GF Value™: kr1,615.96 vs. price of kr1,610.00 (0.4% below fair value)
Industry Position: 186.3% above the Medical Devices & Instruments median (#715 of 809)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
64GF Score
Get the complete analysis for CHIX:QLINES
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 
